Floatz logo

Enitociclib

Lymphoid Malignancies

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Lymphoid Malignancies cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Case Comprehensive Cancer Center
Phase 2BB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 2BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
M.D. Anderson Cancer Center
Phase 2B
Abt-263
AbbVie
Phase 1/2B
Fludarabine
M.D. Anderson Cancer Center
Phase 2B

View all 33 →

Same molecule, other indications

Enitociclib is also rated in:

NHLDormant
CCC
Indicative ·
51 / 100
View asset →
non-Hodgkin lymphomaDormant
CC
Indicative ·
47 / 100
View asset →
hematopoietic and lymphoid system neoplasmDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →